BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Metabolic Anti-Inflammatory Therapy

For biotech investors, medical innovators, and health-tech enthusiasts — this New to The Street interview features BioVie’s CEO, sharing how the company is advancing a new approach to treating Alzheimer’s, Parkinson’s disease, and Long COVID by targeting the central metabolic and inflammatory drivers of neurological illness.

Unlike single-pathway drug development strategies, BioVie believes disease progression is rooted in immune activation, insulin resistance, and reduced blood flow to the brain. Its drug candidate suppresses TNF-alpha at a central inflammatory control point, blocks harmful immune signaling triggered by viral fragments associated with Long COVID, and importantly crosses the blood–brain barrier to work directly within the central nervous system.

The conversation challenges the long-term viability of GLP-1 weight-loss drugs, noting that while they induce short-term weight reduction, they often result in muscle loss, intolerance, and rebound weight gain. BioVie outlines a more durable obesity strategy that pairs GLP-1 therapy for early weight loss with future GIP-targeting treatments designed to prevent fat cell regeneration.

In Parkinson’s research, BioVie’s treatment has demonstrated the ability to reverse insulin resistance and increase oxygen delivery to the brain, two critical factors tied to disease progression and motor symptoms. The company’s Parkinson’s trial is expected to be fully enrolled by year-end, with top-line results anticipated in Q2 next year.

BioVie’s Long COVID trials are ramping nationwide with major academic centers now enrolling patients, reflecting growing interest in CNS-penetrant therapies capable of suppressing viral-driven immune inflammation.

Across all programs, BioVie’s strategy focuses on disease modification rather than symptomatic relief, positioning the company as a leader in metabolic-immunology approaches to central nervous system disorders.

#NewToTheStreet #BioVie #Biotechnology #AlzheimersResearch #ParkinsonsDisease #LongCovid #Neuroinflammation #MetabolicDisease #TNFalpha #BloodBrainBarrier #CNSDrugs #ClinicalTrials #MedicalInnovation #BiotechStocks #DrugDevelopment #Neurodegenerative #HealthcareInvesting #PrecisionMedicine #Immunology #BrainHealth #PharmaInnovation #GrowthBiotech #InvestorInsights